Details for New Drug Application (NDA): 210833
✉ Email this page to a colleague
The generic ingredient in SYMPAZAN is clobazam. There are ten drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the clobazam profile page.
Summary for 210833
Tradename: | SYMPAZAN |
Applicant: | Otter Pharms |
Ingredient: | clobazam |
Patents: | 3 |
Pharmacology for NDA: 210833
Mechanism of Action | Cytochrome P450 2D6 Inhibitors Cytochrome P450 3A4 Inducers |
Suppliers and Packaging for NDA: 210833
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
SYMPAZAN | clobazam | FILM;ORAL | 210833 | NDA | Aquestive Therapeutics | 10094-205 | 10094-205-60 | 60 POUCH in 1 PACKAGE (10094-205-60) / 1 FILM in 1 POUCH (10094-205-01) |
SYMPAZAN | clobazam | FILM;ORAL | 210833 | NDA | Aquestive Therapeutics | 10094-210 | 10094-210-60 | 60 POUCH in 1 PACKAGE (10094-210-60) / 1 FILM in 1 POUCH (10094-210-01) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | FILM;ORAL | Strength | 5MG | ||||
Approval Date: | Nov 1, 2018 | TE: | RLD: | Yes | |||||
Patent: | ⤷ Sign Up | Patent Expiration: | Jan 31, 2040 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patented Use: | METHOD OF TREATING SEIZURES | ||||||||
Patent: | ⤷ Sign Up | Patent Expiration: | Apr 3, 2024 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patent: | ⤷ Sign Up | Patent Expiration: | Feb 20, 2024 | Product Flag? | Y | Substance Flag? | Delist Request? |
Expired US Patents for NDA 210833
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Otter Pharms | SYMPAZAN | clobazam | FILM;ORAL | 210833-003 | Nov 1, 2018 | ⤷ Sign Up | ⤷ Sign Up |
Otter Pharms | SYMPAZAN | clobazam | FILM;ORAL | 210833-001 | Nov 1, 2018 | ⤷ Sign Up | ⤷ Sign Up |
Otter Pharms | SYMPAZAN | clobazam | FILM;ORAL | 210833-002 | Nov 1, 2018 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription